McIver Lindsey A., Siddique Momin S.
The Brooklyn Hospital Center
SIU
HMG-CoA reductase inhibitors (statins) are lipid-lowering medications used in the primary, secondary, and tertiary prevention of coronary heart disease. Atorvastatin is a medication primarily used to manage and treat dyslipidemias and prevent cardiovascular disease. This activity focuses on the indications, mechanism of action, and contraindications of atorvastatin as a valuable agent in managing these conditions. The activity reviews the warnings, adverse event profile, toxicity, and key considerations, including monitoring and relevant drug interactions. Understanding the intricate pharmacology of atorvastatin enables healthcare professionals to tailor treatment plans to individual patient needs. Notably, the emphasis lies on empowering healthcare professionals, highlighting the essential role of the interprofessional healthcare team in managing atorvastatin therapy for hyperlipidemia and reducing cardiovascular risk.
HMG-CoA还原酶抑制剂（他汀类药物）是用于冠心病一级、二级和三级预防的降脂药物。阿托伐他汀竞争性抑制3-羟基-3-甲基戊二酰辅酶A（HMG-CoA）还原酶。通过阻止HMG-CoA转化为甲羟戊酸，他汀类药物可减少肝脏中的胆固醇生成。阿托伐他汀还可增加肝细胞表面低密度脂蛋白受体的数量。本活动回顾了阿托伐他汀治疗冠心病和家族性血脂异常的适应症、禁忌症及作用机制，涵盖了阿托伐他汀治疗的适应症、禁忌症、活性、不良事件及其他关键要素。
